EQUITY RESEARCH MEMO
OncoOne
Generated 5/9/2026
Executive Summary
Conviction (model self-assessment)30/100
OncoOne is a private Austrian biotechnology company founded in 2016 that develops precision cancer medicines. The company leverages two proprietary platform technologies to create targeted therapies, including radiopharmaceuticals, aimed at improving outcomes for patients with challenging cancers with significant unmet medical needs. Despite a focused approach, the company is early-stage with no disclosed pipeline or financial details, limiting visibility into its progress and potential.
Upcoming Catalysts (preview)
- TBDNext financing round or partnership announcement40% success
- TBDIND filing for lead candidate25% success
- TBDInitial preclinical or clinical data release20% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)